Driver D A, Polo J M, Belli B A, Banks T A, Hariharan M, Dubensky T W
Department of Viral Therapeutics, Chiron Technologies Center for Gene Therapy, 11055 Roselle Street, San Diego, CA 92121, USA.
IDrugs. 1998 Oct;1(6):678-85.
Alphavirus-derived vectors are being developed for vaccine, gene therapy and recombinant protein production applications, based in part on observations of transient, high level expression of heterologous genes in eukaryotic cells. Efficient means for launching the RNA alphavirus genome from RNA polymerase II expression cassettes have been developed, obviating the need for transcription in vitro of long cDNA templates. One system being developed from this technology is a layered plasmid DNA vector which, when inoculated directly into animal muscle, launches a self-amplifying alphavirus vector, resulting in subsequent induction of comparatively robust immune responses specific for the expressed antigen.
基于在真核细胞中异源基因短暂、高水平表达的观察结果，正开发源自甲病毒的载体用于疫苗、基因治疗和重组蛋白生产应用。已开发出从RNA聚合酶II表达盒启动RNA甲病毒基因组的有效方法，无需体外转录长cDNA模板。基于该技术正在开发的一个系统是分层质粒DNA载体，当直接接种到动物肌肉中时，可启动自我扩增的甲病毒载体，从而随后诱导针对所表达抗原的相对较强的免疫反应。
